FDA Clears Datar Cancer Genetics’ CellDx-Tissue for Comprehensive Genomic Profiling of Solid Tumors

In a significant advancement for precision oncology, Datar Cancer Genetics (DCG) has announced that its tissue-based comprehensive genomic profiling (CGP) assay, CellDx-Tissue, has received clearance from the U.S. Food and Drug Administration (FDA).

This clearance marks a major milestone in the ability of oncologists to access detailed molecular insights, allowing for more personalized clinical management decisions for patients battling various solid tumors.

Understanding CellDx-Tissue: A Dual-Analyte Approach

CellDx-Tissue is a qualitative in vitro diagnostic (IVD) test designed to provide a deep dive into the genetic makeup of a tumor. Unlike traditional testing methods that may focus on a single type of genetic material, CellDx-Tissue utilizes targeted Next-Generation Sequencing (NGS) to analyze both DNA and RNA.

The assay is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue, which is the standard specimen used in many pathology departments. By analyzing both DNA and RNA, the platform offers a more complete picture of the tumor’s landscape than DNA sequencing alone.

The Science of DNA and RNA Integration

The integration of both analytes is critical for identifying different types of genetic alterations:

• DNA Analysis: Identifies somatic single nucleotide variants (SNVs), tiny insertions and deletions (InDels) and gene amplifications, such as ERBB2.
• RNA Analysis: Provides essential evidence for detecting gene fusions, specifically involving ALK, RET, and ROS1.

By covering 517 cancer-associated genes, this dual-analyte workflow ensures that clinicians do not miss vital information that could dictate the success of a specific therapeutic intervention.

Clinical Significance in Precision Oncology

Comprehensive genomic profiling has transitioned from a specialized research tool to a central component of clinical management for solid tumors. The goal of precision oncology is to move away from a “one-size-fits-all” approach and instead tailor treatments to the unique molecular signature of an individual’s cancer.

The FDA clearance of CellDx-Tissue provides oncologists with a robust platform to characterize tumor genomic alterations across a broad spectrum of cancer types. This information is vital for:

• Identifying actionable mutations that can be targeted with specific drugs.
• Informing clinical management in accordance with professional medical guidelines.
• Optimizing treatment strategies to improve patient outcomes.

The assay is performed at Datar Cancer Genetics’ laboratory, which maintains both CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accreditation, ensuring high standards of quality and reliability in diagnostic reporting.

Key Takeaways

• FDA Clearance: CellDx-Tissue is now cleared by the US FDA for use in solid tumor genomic profiling.
• Comprehensive Scope: The assay analyzes 517 cancer-associated genes.
• Dual-Analyte Technology: Uses both DNA and RNA sequencing to identify SNVs, InDels, amplifications, and gene fusions.
• Clinical Utility: Supports personalized clinical decision-making for oncologists globally.
• Accredited Testing: Performed in CAP- and CLIA-accredited laboratory settings.

Frequently Asked Questions

What makes CellDx-Tissue different from standard genetic tests?

Most standard tests focus primarily on DNA. CellDx-Tissue’s “dual-analyte” approach includes RNA sequencing. This is crucial because certain genetic changes, like gene fusions (e.g., ALK, RET, ROS1), are often more clearly and accurately identified through RNA analysis, providing a more comprehensive view of the tumor’s drivers.

What kind of samples are required for this test?

The assay is designed for use with formalin-fixed paraffin-embedded (FFPE) tumor tissue. This is the standard type of tissue sample typically collected during a tumor biopsy.

How does this clearance benefit cancer patients?

By providing a more detailed map of the genetic mutations driving a tumor, CellDx-Tissue helps doctors select therapies that are most likely to be effective for a specific patient’s cancer profile. This precision can lead to more effective treatments and better-informed clinical management.